허셉틴(Herceptin) 시장 : 시장 분석 및 예측 - 유형별, 제품별, 용도별, 최종 사용자별, 기술별, 전개별, 서비스별, 단계별, 컴포넌트별, 솔루션별(-2035년)

Herceptin Market is anticipated to expand from $4.29 billion in 2024 to $6.33 billion by 2034, growing at a CAGR of approximately 4%. The Herceptin Market encompasses the sale and distribution of trastuzumab, a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer and gastric cancer. This market is driven by increasing cancer prevalence, advancements in biologic therapies, and the expansion of healthcare infrastructure globally. Key players focus on biosimilar development and strategic partnerships to enhance market reach. The demand for personalized medicine and targeted therapies continues to propel market growth, emphasizing the importance of innovation and regulatory approvals.

The Herceptin Market is experiencing robust growth, propelled by increasing incidence of HER2-positive breast cancer and advancements in oncology treatments. The therapeutic segment dominates, with intravenous formulations being the top-performing sub-segment due to established efficacy and widespread clinical use. Subcutaneous formulations are emerging as the second highest-performing sub-segment, driven by patient preference for convenience and reduced administration time. Biosimilars are gaining traction, offering cost-effective alternatives and expanding accessibility. The diagnostic segment follows, with companion diagnostics playing a pivotal role in treatment personalization and precision medicine. Immunohistochemistry tests lead in performance, as they are critical for determining HER2 status. Fluorescence in situ hybridization tests are the second leading sub-segment, providing complementary insights for accurate diagnosis. Innovations in liquid biopsy technologies are poised to enhance early detection and monitoring, further fueling market growth. Collaborative efforts between pharmaceutical companies and diagnostic firms are fostering advancements in personalized cancer care.

Market Snapshot:

In the Herceptin market, market share is dominated by a few key players, with pricing strategies reflecting the competitive landscape and therapeutic value. Recent product launches have introduced biosimilars, which are gaining traction due to their cost-effectiveness and comparable efficacy. The market is witnessing a shift towards personalized medicine, influencing pricing dynamics and market penetration strategies. Companies are leveraging innovation to enhance their portfolios, maintaining a competitive edge in an evolving market environment. Competition in the Herceptin market is intense, with companies striving for differentiation through R&D and strategic alliances. Regulatory influences are pivotal, with stringent guidelines shaping market entry and product development. Benchmarking against competitors reveals a focus on biosimilar development and market expansion in emerging regions. North America and Europe remain key markets, while Asia-Pacific is experiencing accelerated growth due to increased healthcare investments. Regulatory frameworks in these regions dictate market dynamics, presenting both challenges and opportunities for stakeholders.

Geographical Overview:

The Herceptin market exhibits varied dynamics across different regions, highlighting distinct growth opportunities. North America maintains a dominant position, propelled by advanced healthcare infrastructure and substantial investments in oncology research. The region's robust healthcare policies and increasing prevalence of breast cancer further bolster market growth. Europe follows closely, driven by significant investments in biosimilars and an emphasis on innovative cancer treatments. The region's focus on improving healthcare access and affordability enhances its market potential. In the Asia Pacific, rapid market expansion is evident, fueled by growing healthcare awareness and increasing incidence of cancer. Rising investments in healthcare infrastructure and research in countries like China and India contribute to this growth. Latin America and the Middle East & Africa present emerging opportunities, with increasing healthcare investments and a focus on improving cancer treatment accessibility. Brazil and South Africa are key markets, recognizing the importance of advanced therapeutics like Herceptin in addressing healthcare challenges and improving patient outcomes.

Key Trends and Drivers:

The Herceptin market is experiencing robust growth driven by advancements in personalized medicine and targeted therapies. Key trends include increased adoption of biosimilars, which offer cost-effective alternatives to branded Herceptin. This trend is particularly significant in emerging markets, where healthcare budgets are constrained. Additionally, the integration of Herceptin in combination therapies is gaining momentum, enhancing treatment efficacy and patient outcomes. The expanding prevalence of HER2-positive breast cancer is a primary driver, necessitating effective treatment options like Herceptin. Growing awareness and early diagnosis are further accelerating market demand. Technological innovations in drug delivery systems are improving administration efficiency, broadening Herceptin's application scope. Moreover, strategic partnerships and collaborations between biotech firms and pharmaceutical giants are fostering research and development, leading to novel therapeutic solutions. Opportunities abound in regions with rising healthcare infrastructure investments, where accessibility to advanced cancer treatments is improving. Companies investing in market education and patient support programs are likely to capture significant market share. The Herceptin market is poised for sustained expansion as precision medicine continues to evolve, offering promising avenues for innovation and growth.

Restraints and Challenges:

The Herceptin market is confronted with several significant restraints and challenges. A primary restraint is the expiration of key patents, paving the way for biosimilar competition and reducing market share for original manufacturers. Consequently, pricing pressures intensify, affecting profit margins. Regulatory complexities in the approval of biosimilars add another layer of challenge, as navigating these can be time-consuming and costly. Furthermore, the high cost of Herceptin and its biosimilars remains a significant barrier, limiting access in low-income regions and straining healthcare budgets. The market also faces challenges in effectively educating healthcare providers and patients about biosimilars to ensure trust and acceptance. Lastly, the emergence of alternative therapies targeting HER2-positive breast cancer introduces competitive pressures, compelling stakeholders to innovate continuously. These dynamics collectively pose substantial challenges to maintaining growth and market dominance.

Key Players:

Biocon, Celltrion, Samsung Bioepis, Mabion, Prestige BioPharma, Henlius Biotech, Amgen, Teva Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Zydus Cadila, Bio-Thera Solutions, Epirus Biopharmaceuticals, Oncobiologics, Alvotech, Gedeon Richter, Coherus BioSciences, Apotex, Intas Pharmaceuticals, Shanghai Fosun Pharmaceutical

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Application
• 2.4 Key Market Highlights by End User
• 2.5 Key Market Highlights by Technology
• 2.6 Key Market Highlights by Deployment
• 2.7 Key Market Highlights by Services
• 2.8 Key Market Highlights by Stage
• 2.9 Key Market Highlights by Component
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Monoclonal Antibodies
  • 4.1.2 Biosimilars
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Intravenous Herceptin
  • 4.2.2 Subcutaneous Herceptin
• 4.3 Market Size & Forecast by Application (2020-2035)
  • 4.3.1 Breast Cancer
  • 4.3.2 Gastric Cancer
• 4.4 Market Size & Forecast by End User (2020-2035)
  • 4.4.1 Hospitals
  • 4.4.2 Cancer Treatment Centers
  • 4.4.3 Research Institutes
• 4.5 Market Size & Forecast by Technology (2020-2035)
  • 4.5.1 Recombinant DNA Technology
  • 4.5.2 Hybridoma Technology
• 4.6 Market Size & Forecast by Deployment (2020-2035)
  • 4.6.1 Inpatient Care
  • 4.6.2 Outpatient Care
• 4.7 Market Size & Forecast by Services (2020-2035)
  • 4.7.1 Patient Assistance Programs
  • 4.7.2 Clinical Trial Services
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Early Stage
  • 4.8.2 Metastatic Stage
• 4.9 Market Size & Forecast by Component (2020-2035)
  • 4.9.1 Active Pharmaceutical Ingredient (API)
  • 4.9.2 Excipients
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Personalized Medicine Solutions
  • 4.10.2 Companion Diagnostics

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Application
    • 5.2.1.4 End User
    • 5.2.1.5 Technology
    • 5.2.1.6 Deployment
    • 5.2.1.7 Services
    • 5.2.1.8 Stage
    • 5.2.1.9 Component
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Application
    • 5.2.2.4 End User
    • 5.2.2.5 Technology
    • 5.2.2.6 Deployment
    • 5.2.2.7 Services
    • 5.2.2.8 Stage
    • 5.2.2.9 Component
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Application
    • 5.2.3.4 End User
    • 5.2.3.5 Technology
    • 5.2.3.6 Deployment
    • 5.2.3.7 Services
    • 5.2.3.8 Stage
    • 5.2.3.9 Component
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Application
    • 5.3.1.4 End User
    • 5.3.1.5 Technology
    • 5.3.1.6 Deployment
    • 5.3.1.7 Services
    • 5.3.1.8 Stage
    • 5.3.1.9 Component
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Application
    • 5.3.2.4 End User
    • 5.3.2.5 Technology
    • 5.3.2.6 Deployment
    • 5.3.2.7 Services
    • 5.3.2.8 Stage
    • 5.3.2.9 Component
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Application
    • 5.3.3.4 End User
    • 5.3.3.5 Technology
    • 5.3.3.6 Deployment
    • 5.3.3.7 Services
    • 5.3.3.8 Stage
    • 5.3.3.9 Component
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Application
    • 5.4.1.4 End User
    • 5.4.1.5 Technology
    • 5.4.1.6 Deployment
    • 5.4.1.7 Services
    • 5.4.1.8 Stage
    • 5.4.1.9 Component
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Application
    • 5.4.2.4 End User
    • 5.4.2.5 Technology
    • 5.4.2.6 Deployment
    • 5.4.2.7 Services
    • 5.4.2.8 Stage
    • 5.4.2.9 Component
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Application
    • 5.4.3.4 End User
    • 5.4.3.5 Technology
    • 5.4.3.6 Deployment
    • 5.4.3.7 Services
    • 5.4.3.8 Stage
    • 5.4.3.9 Component
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Application
    • 5.4.4.4 End User
    • 5.4.4.5 Technology
    • 5.4.4.6 Deployment
    • 5.4.4.7 Services
    • 5.4.4.8 Stage
    • 5.4.4.9 Component
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Application
    • 5.4.5.4 End User
    • 5.4.5.5 Technology
    • 5.4.5.6 Deployment
    • 5.4.5.7 Services
    • 5.4.5.8 Stage
    • 5.4.5.9 Component
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Application
    • 5.4.6.4 End User
    • 5.4.6.5 Technology
    • 5.4.6.6 Deployment
    • 5.4.6.7 Services
    • 5.4.6.8 Stage
    • 5.4.6.9 Component
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Application
    • 5.4.7.4 End User
    • 5.4.7.5 Technology
    • 5.4.7.6 Deployment
    • 5.4.7.7 Services
    • 5.4.7.8 Stage
    • 5.4.7.9 Component
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Application
    • 5.5.1.4 End User
    • 5.5.1.5 Technology
    • 5.5.1.6 Deployment
    • 5.5.1.7 Services
    • 5.5.1.8 Stage
    • 5.5.1.9 Component
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Application
    • 5.5.2.4 End User
    • 5.5.2.5 Technology
    • 5.5.2.6 Deployment
    • 5.5.2.7 Services
    • 5.5.2.8 Stage
    • 5.5.2.9 Component
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Application
    • 5.5.3.4 End User
    • 5.5.3.5 Technology
    • 5.5.3.6 Deployment
    • 5.5.3.7 Services
    • 5.5.3.8 Stage
    • 5.5.3.9 Component
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Application
    • 5.5.4.4 End User
    • 5.5.4.5 Technology
    • 5.5.4.6 Deployment
    • 5.5.4.7 Services
    • 5.5.4.8 Stage
    • 5.5.4.9 Component
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Application
    • 5.5.5.4 End User
    • 5.5.5.5 Technology
    • 5.5.5.6 Deployment
    • 5.5.5.7 Services
    • 5.5.5.8 Stage
    • 5.5.5.9 Component
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Application
    • 5.5.6.4 End User
    • 5.5.6.5 Technology
    • 5.5.6.6 Deployment
    • 5.5.6.7 Services
    • 5.5.6.8 Stage
    • 5.5.6.9 Component
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Application
    • 5.6.1.4 End User
    • 5.6.1.5 Technology
    • 5.6.1.6 Deployment
    • 5.6.1.7 Services
    • 5.6.1.8 Stage
    • 5.6.1.9 Component
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Application
    • 5.6.2.4 End User
    • 5.6.2.5 Technology
    • 5.6.2.6 Deployment
    • 5.6.2.7 Services
    • 5.6.2.8 Stage
    • 5.6.2.9 Component
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Application
    • 5.6.3.4 End User
    • 5.6.3.5 Technology
    • 5.6.3.6 Deployment
    • 5.6.3.7 Services
    • 5.6.3.8 Stage
    • 5.6.3.9 Component
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Application
    • 5.6.4.4 End User
    • 5.6.4.5 Technology
    • 5.6.4.6 Deployment
    • 5.6.4.7 Services
    • 5.6.4.8 Stage
    • 5.6.4.9 Component
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Application
    • 5.6.5.4 End User
    • 5.6.5.5 Technology
    • 5.6.5.6 Deployment
    • 5.6.5.7 Services
    • 5.6.5.8 Stage
    • 5.6.5.9 Component
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Biocon
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Celltrion
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Samsung Bioepis
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Mabion
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Prestige BioPharma
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Henlius Biotech
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Amgen
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Teva Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Mylan
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Dr. Reddy's Laboratories
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Zydus Cadila
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bio-Thera Solutions
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Epirus Biopharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Oncobiologics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Alvotech
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Gedeon Richter
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Coherus BioSciences
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Apotex
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Intas Pharmaceuticals
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Shanghai Fosun Pharmaceutical
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us